ReviewProstate international2017
Review in Prostate international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04053842 (Multi-modality Prostate Cancer Image Guided Interventions - 5), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-modality Prostate Cancer Image Guided Interventions - 5
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- Trial
- End-to-end [Abdominal radiology (New York) · 2025Article
- Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.Cancers · 2023Review
- [Positron emission tomography in oncology].Radiologie (Heidelberg, Germany) · 2023Article
- Irreversible electroporation for prostate cancer using PSMA PET-CT.Prostate international · 2023Article
- Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence.Urologic oncology · 2023Article
- Development and validation ofEJNMMI research · 2022Article
- Cribriform pattern disease over-represented in pelvic lymph node metastases identified onBJUI compass · 2022Article
- Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.Cancer science · 2021Article
- Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.Nature reviews. Urology · 2020Review
- Good clinical practice recommendations for the use of PET/CT in oncology.European journal of nuclear medicine and molecular imaging · 2020Article
- Imaging modalities in synchronous oligometastatic prostate cancer.World journal of urology · 2019Review
- A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).Molecular imaging and biology · 2019Review
- Phase I Study of CTT1057, anJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.Molecular and clinical oncology · 2019Article
- Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.American journal of nuclear medicine and molecular imaging · 2018Review
- Dynamic 11C-Choline PET / CT for the primary diagnosis of prostate cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy. Prostate-specific membrane antigen (PSMA) is overexpressed in prostatic cancer cells. Novel imaging modalities using radiolabeled tracers with PSMA such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.